PREVALENCE OF CYP2D6*4 AND ITS POSSIBLE RELATION TO THERAPEUTIC OUTCOMES OF ADJUVANT TAMOXIFEN THERAPY IN EGYPTIAN PREMENOPAUSAL WOMEN WITH BREAST CANCER | ||||
Bulletin of Pharmaceutical Sciences Assiut University | ||||
Volume 45, Issue 2, December 2022, Page 935-951 PDF (1.1 MB) | ||||
Document Type: Original Article | ||||
DOI: 10.21608/bfsa.2022.271774 | ||||
View on SCiNiTO | ||||
Authors | ||||
Mohammad Salem Hareedy1; Amira F. Taha 2; Abeer Ibrahim3; Medhat A. Saleh4; Mohamed A. Abdelrady5; Ehab S. EL Desoky1 | ||||
1Department of Pharmacology, Faculty of Medicine, Assiut University, Egypt. | ||||
2Department of Pharmacology and Toxicology, Faculty of Pharmacy, Assiut University, Egypt. | ||||
3Department of Medical Oncology and Hematological Malignancy, South Egypt Cancer Institute, Assiut University, Egypt. | ||||
4Department of Public Health and Community Medicine, Assiut University, Egypt. | ||||
5Faculty of Medicine, Assiut University, Egypt. | ||||
Abstract | ||||
Background: Although tamoxifen is a main adjuvant therapy in estrogen positive breast cancer especially in premenopausal women, reliance on genetic polymorphisms of its CYP2D6 metabolizing enzyme and/or therapeutic drug monitoring of its active metabolite, endoxifen to determine tamoxifen-therapeutic outcomes is debatable. Objective: The goal of the study was to investigate the prevalence of CYP2D6*4 and possible association between its nonfunctional allele (A) and both tamoxifen-induced adverse effects and cancer relapse in premenopausal breast cancer patients. Method:Polymerase chain reaction -restriction fragment length polymorphism (PCR-RFLP) analysis was applied for detection of CYP2D6*4 (1846 G>A) genotypes. Results:Genotyping analysis of CYP2D6*4 showed a minimal allele frequency of 23%. Increased endometrial thickness in mm was significantly correlated with CYP2D6*4 GA and AA genotypes in comparison with GG genotypes (P< 0.01). No other relations were found between CYP2D6*4 alleles and other tamoxifen adverse effects (P > 0.9) or cancer relapse (P= 0.7). Conclusion: The prevalence of CYP2D6*4 polymorphism in Egyptian premenopausal females with breast cancer who are given tamoxifen is similar to that in Caucasians. The nonfunctional allele (A-allele) of CYP2D6*4 showed a significant association with increased endometrial thickness possibly related to tamoxifen, but no association with other drug adverse effects or cancer relapse. | ||||
Keywords | ||||
Tamoxifen; CYP2D6*4; premenopausal Egyptian females; breast cancer | ||||
Statistics Article View: 133 PDF Download: 173 |
||||